These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20085496)

  • 1. A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.
    Vanpouille C; Lisco A; Derudas M; Saba E; Grivel JC; Brichacek B; Scrimieri F; Schinazi R; Schols D; McGuigan C; Balzarini J; Margolis L
    J Infect Dis; 2010 Feb; 201(4):635-43. PubMed ID: 20085496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
    Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
    N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
    Watson-Jones D; Wald A; Celum C; Lingappa J; Weiss HA; Changalucha J; Baisley K; Tanton C; Hayes RJ; Marshak JO; Gladden RG; Koelle DM
    J Clin Microbiol; 2010 Oct; 48(10):3496-503. PubMed ID: 20702659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV).
    Arinze F; Shaver A; Raffanti S
    Infection; 2017 Oct; 45(5):705-707. PubMed ID: 28508238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
    Derudas M; Vanpouille C; Carta D; Zicari S; Andrei G; Snoeck R; Brancale A; Margolis L; Balzarini J; McGuigan C
    J Med Chem; 2017 Sep; 60(18):7876-7896. PubMed ID: 28829913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir.
    Balzarini J; Haller-Meier F; De Clercq E; Meier C
    Antivir Chem Chemother; 2001 Sep; 12(5):301-6. PubMed ID: 11900349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
    Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
    J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
    Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
    Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of penciclovir in antiviral assays against herpes simplex virus.
    Bacon TH; Howard BA; Spender LC; Boyd MR
    J Antimicrob Chemother; 1996 Feb; 37(2):303-13. PubMed ID: 8707740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.
    Barnabas RV; Celum C
    Curr HIV Res; 2012 Apr; 10(3):228-37. PubMed ID: 22384842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
    Andrei G; Gillemot S; Topalis D; Snoeck R
    J Infect Dis; 2018 Feb; 217(5):790-801. PubMed ID: 29186456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro.
    Zakirova NF; Shipitsyn AV; Jasko MV; Prokofjeva MM; Andronova VL; Galegov GA; Prassolov VS; Kochetkov SN
    Bioorg Med Chem; 2012 Oct; 20(19):5802-9. PubMed ID: 22954898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.
    Mujugira A; Magaret AS; Celum C; Baeten JM; Lingappa JR; Morrow RA; Fife KH; Delany-Moretlwe S; de Bruyn G; Bukusi EA; Karita E; Kapiga S; Corey L; Wald A;
    J Infect Dis; 2013 Nov; 208(9):1366-74. PubMed ID: 23901094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus.
    Hostetler KY; Parker S; Sridhar CN; Martin MJ; Li JL; Stuhmiller LM; van Wijk GM; van den Bosch H; Gardner MF; Aldern KA
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11835-9. PubMed ID: 8265634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
    McMahon MA; Siliciano JD; Kohli RM; Siliciano RF
    AIDS; 2010 Jan; 24(2):319-23. PubMed ID: 20009920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.
    McNicholl JM; Leelawiwat W; Whitehead S; Hanson DL; Evans-Strickfaden T; Cheng CY; Chonwattana W; Mueanpai F; Kittinunvorakoon C; Markowitz L; Dunne EF
    Int J STD AIDS; 2017 Mar; 28(4):372-379. PubMed ID: 27179350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity.
    Balzarini J; Andrei G; Balestra E; Huskens D; Vanpouille C; Introini A; Zicari S; Liekens S; Snoeck R; Holý A; Perno CF; Margolis L; Schols D
    PLoS Pathog; 2013; 9(7):e1003456. PubMed ID: 23935482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.
    Eide K; Moerdyk-Schauwecker M; Stein DA; Bildfell R; Koelle DM; Jin L
    Antivir Ther; 2010; 15(8):1141-9. PubMed ID: 21149921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man.
    Henao-Martínez AF; Weinberg A; Waldman WJ; Levi ME
    J Clin Virol; 2012 Jul; 54(3):276-8. PubMed ID: 22465339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
    Lisco A; Vanpouille C; Tchesnokov EP; Grivel JC; Biancotto A; Brichacek B; Elliott J; Fromentin E; Shattock R; Anton P; Gorelick R; Balzarini J; McGuigan C; Derudas M; Götte M; Schinazi RF; Margolis L
    Cell Host Microbe; 2008 Sep; 4(3):260-270. PubMed ID: 18779052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.